

HR 1790

Biologics Competition Act of 2023

Congress: 118 (2023–2025, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 24, 2023

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Mar 31, 2023)

Official Text: <https://www.congress.gov/bill/118th-congress/house-bill/1790>

Sponsor

Name: Rep. Miller-Meeks, Mariannette [R-IA-1]

Party: Republican • **State:** IA • **Chamber:** House

Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Barragan, Nanette Diaz [D-CA-44]	D · CA		Mar 24, 2023
Rep. Kuster, Ann M. [D-NH-2]	D · NH		Mar 24, 2023
Rep. Murphy, Gregory F. [R-NC-3]	R · NC		Mar 24, 2023
Rep. Crenshaw, Dan [R-TX-2]	R · TX		Apr 3, 2023

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 31, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Biologics Competition Act of 2023

This bill requires the Food and Drug Administration (FDA) to evaluate (1) the differences between the requirements that apply to interchangeable biologics and the requirements that apply to therapeutically equivalent ratings for generic drugs, and (2) the effects of these differences on the approval of interchangeable biologics. The FDA must update the Purple Book with changes that better align the ways these requirements are communicated while still maintaining each distinct approval pathway.

The Purple Book is an FDA publication that lists approved biological products, including biosimilars and interchangeable biologics. Interchangeable biologics are biologics that may be substituted for the original product without consulting the prescriber, similar to how generic drugs may be substituted for brand-name drugs based on therapeutic equivalence.

Actions Timeline

- **Mar 31, 2023:** Referred to the Subcommittee on Health.
- **Mar 24, 2023:** Introduced in House
- **Mar 24, 2023:** Referred to the House Committee on Energy and Commerce.